|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:activeIngredient
|
gptkb:paliperidone
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:ATCCode
|
N05AX13
|
|
gptkbp:brand
|
paliperidone palmitate
|
|
gptkbp:chemicalClass
|
antipsychotic medication
|
|
gptkbp:contraindication
|
hypersensitivity to paliperidone
|
|
gptkbp:duration
|
3 months
|
|
gptkbp:firstDoseRequirement
|
requires prior treatment with Invega Sustenna
|
|
gptkbp:form
|
extended-release injectable suspension
|
|
gptkbp:frequency
|
every 3 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invega Trinza
|
|
gptkbp:indication
|
maintenance treatment of schizophrenia in adults
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:relatedTo
|
gptkb:Invega_Sustenna
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
weight gain
drowsiness
injection site reactions
extrapyramidal symptoms
increased prolactin
|
|
gptkbp:storage
|
2°C to 25°C
|
|
gptkbp:usedFor
|
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Invega
|
|
gptkbp:bfsLayer
|
6
|